Open AccessLiraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model
Author(s) -
Zhimin Wang,
Mengjun Wang,
Xiaofan Hu,
Yakun Li,
Dongxia Ma,
Shang-Lin Li,
Gaoping Zhao,
Yanan Xie,
Yan-Wen Shu,
Jun Yang
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002448
Subject(s) - liraglutide , medicine , cardiac fibrosis , transplantation , downregulation and upregulation , fibrosis , heart transplantation , agonist , endocrinology , inflammation , receptor , immunology , diabetes mellitus , biology , type 2 diabetes , biochemistry , gene
Advances in immunosuppressive therapy have significantly improved short-term but not long-term survival of cardiac transplant recipients; this is largely due to severe cardiac allograft vasculopathy (CAV). Glucagon-like peptide-1 receptor (GLP-1R)-based therapy exerts physiological effects on the cardiovascular system in addition to its traditional role in controlling glucose. We have investigated the effects of liraglutide, a GLP-1R agonist, on the development of CAV in a murine heart transplant model.